Paclitaxel‐carboplatin‐gemcitabine (TCG) as first‐line treatment of ovarian cancer: a prospective multicenter phase II study (AGO‐OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO‐OVAR 9, GINECO‐TCG, NSGO‐OC‐0102) comparing TCG with standard TC

Andreas du Bois,Jalid Sehouli,Bente Lund,Florence Joly,J. Huober,T.S. Jensen,E. Levy,V. Heilmann,Karin Boman,Anne Claire Hardy-Bessard,Alexander Burges,Johanna Mäenpää,E. Pujade-Lauraine,J. Pfisterer,M. Gropp,A. Staehle,Pauline Wimberger,Christian Jackisch,Barbara Schmalfeldt,A. Belau,Sibylle Loibl,Kerstin Wollschlaeger,Ulrich Canzler,Justine Rochon

Paclitaxel‐carboplatin‐gemcitabine (TCG) as first‐line treatment of ovarian cancer: a prospective multicenter phase II study (AGO‐OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO‐OVAR 9, GINECO‐TCG, NSGO‐OC‐0102) comparing TCG with standard TC

2005

Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

Keywords:

Ovarian cancer
Phases of clinical research
Gynecology
Paclitaxel carboplatin
Gemcitabine
Medicine
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations